Generalized Pustular Psoriasis Clinical Trial
Official title:
Genetics-based Efficacy Analysis: Ustekinumab Versus Secukinumab for the Treatment of Generalized Pustular Psoriasis
The investigators aim to compare the efficacy and safety of secukinumab and ustekinumab in patients with generalized pustular psoriasis (GPP), and to explore the impact of genetic mutation types on clinical efficacy. The main questions the study aims to answer are: Is there a difference in the effectiveness of secukinumab and ustekinumab in the treatment of GPP? How is the safety of secukinumab and ustekinumab in the treatment of GPP? Does the type of genetic mutation in GPP patients affect the efficacy of secukinumab and ustekinumab? The investigators will compare patients treated with secukinumab to those treated with ustekinumab to see the difference in the effectiveness of the two drugs in treating GPP. Participants will: The investigators conducted a 48-week follow-up study on 65 participants who were admitted to the dermatology department of the First Affiliated Hospital of Fujian Medical University for GPP from July 2019 to December 2022. All participants underwent saliva-based genetic testing. Efficacy analyses were performed based on the scores of Generalized Pustular Psoriasis Area and Severity Index (GPPASI) and Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) at week 0, 2, 4, 12, 24, and 48. Participants were also asked to report all adverse events (AEs) during follow-up.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06100991 -
CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry
|
||
| Recruiting |
NCT06013969 -
A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares
|
Phase 4 | |
| Completed |
NCT05512598 -
HB0034 in Patients With Generalized Pustular Psoriasis (GPP)
|
Phase 1 | |
| Active, not recruiting |
NCT03886246 -
Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study
|
Phase 2 | |
| Recruiting |
NCT05670821 -
PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms
|
||
| Recruiting |
NCT06323356 -
A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
|
Phase 3 | |
| Completed |
NCT05239039 -
An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options
|
Phase 3 | |
| Completed |
NCT04399837 -
A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis
|
Phase 2 | |
| Not yet recruiting |
NCT06433531 -
A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)
|
Phase 1 | |
| Completed |
NCT03942042 -
A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis
|
Phase 4 | |
| Completed |
NCT03782792 -
Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis
|
Phase 2 | |
| Completed |
NCT03619902 -
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis
|
Phase 2 | |
| Active, not recruiting |
NCT04566471 -
Palmoplantar Pustulosis and Generalized Pustular Psoriasis: A National Population-based Analysis of Prevalence
|
||
| Recruiting |
NCT06295692 -
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
|
Phase 3 | |
| Completed |
NCT05200247 -
An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options
|
Phase 3 | |
| Active, not recruiting |
NCT05366855 -
Long-Term Safety and Efficacy of Imsidolimab (ANB019) in Subjects With Generalized Pustular Psoriasis
|
Phase 3 | |
| Completed |
NCT05352893 -
Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
|
Phase 3 |